TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Compendia Publishers Must Tell CMS How They Manage Conflicts Of Interest November 13, 2009
TCL Archive In Surprising Result, Survey Of Centers Finds Little “Crisis” In Clinical Research September 29, 1995
